Shigyo Hirona, Suzuki Hiroyuki, Tanaka Toshimitsu, Moriyama Etsuko, Shimotsuura Yasutaka, Nagasu Sachiko, Iwamoto Hideki, Akagi Yoshito, Murotani Kenta, Kawaguchi Takumi, Miwa Keisuke
Multidisciplinary Treatment Cancer Center, Kurume University Hospital, Kurume 830-0011, Japan.
Department of Surgery, Kurume University School of Medicine, Kurume 830-0011, Japan.
Cancers (Basel). 2023 Apr 12;15(8):2264. doi: 10.3390/cancers15082264.
Bevacizumab (BEV) requires an adequate withdrawal period to avoid BEV-related complications during major surgery. However, the safety of BEV administration immediately after surgical placement of the central venous (CV) port, a minor surgery, is still unclear. This study aimed to investigate whether BEV is safe when administered early after CV port placement. We retrospectively evaluated 184 patients with advanced colorectal cancer (CRC) treated with a BEV-containing regimen and divided them into two groups according to the interval between CV port implantation and chemotherapy initiation, with the early administration group being ≤7 days and late administration group being >7 days. Complications were then compared between the two groups. The early-administration group was significantly older and had a higher rate of colon cancer than the late-administration group. Overall, 24 (13%) patients developed CV port-related complications. Male sex was a risk factor for complications (odds ratio [OR], 3.154; 95% CI, 1.19-8.36). The two groups showed no significant difference in the frequency of complications ( = 0.84) or patient characteristics (after the inverse probability of treatment weighting, = 0.537). In conclusion, the frequency of complications is not affected by the timing of BEV initiation after CV port implantation. Thus, early BEV administration after CV port placement is safe.
贝伐单抗（BEV）需要足够的停药期，以避免在大手术期间出现与BEV相关的并发症。然而，在进行中心静脉（CV）置管这一小型手术后立即给予BEV的安全性仍不明确。本研究旨在调查CV置管后早期给予BEV是否安全。我们回顾性评估了184例接受含BEV方案治疗的晚期结直肠癌（CRC）患者，并根据CV置管与化疗开始之间的间隔将他们分为两组，早期给药组间隔≤7天，晚期给药组间隔>7天。然后比较两组的并发症情况。早期给药组患者年龄显著更大，结肠癌发生率高于晚期给药组。总体而言，24例（13%）患者出现了与CV置管相关的并发症。男性是并发症的一个危险因素（比值比[OR]，3.154；95%置信区间，1.19 - 8.36）。两组在并发症发生率（ = 0.84）或患者特征方面（在进行治疗权重逆概率分析后， = 0.537）无显著差异。总之，并发症的发生率不受CV置管后开始使用BEV时间的影响。因此，CV置管后早期给予BEV是安全的。
